Ultrasonic analysis of anthracycline-induced myocardial damage using cyclic variation of integrated backscatter.
To test the feasibility of integrated backscatter (IB) for detecting anthracycline cardiotoxicity, we performed conventional echocardiography and IB analysis. For interindividual comparison, 32 patients with non-Hodgkin's lymphoma and 14 control subjects were selected. Of the patients, 10 had been treated with doxorubicin doses of </=200 mg/m(2) (low dose), 15 with </=400 mg/m(2) (moderate dose), and 7 with >400 mg/m(2) (high dose). In intraindividual comparison, 8 patients were examined before doxorubicin therapy and at a dose of 100 mg/m(2) and 8 were examined before and at a 300-mg/m(2) dose. Cyclic variation of IB (CV-IB) was obtained at the left ventricular posterior wall, using a modified, commercially available system in M-mode format. In interindividual comparison, CV-IB in high- and moderate-dose groups was smaller. In intraindividual comparison, CV-IB decreased after treatment with 300 mg/m(2) of doxorubicin. CV-IB was affected in some patients treated with a moderate dose of doxorubicin. IB analysis may be helpful for detecting early anthracycline cardiotoxicity.
Nagai
Hideo
H
Department of Cardiology, Kanazawa Red Cross Hospital, Minma 2-251, Kanazawa 921-8162, Japan. hidnagai@ybb.ne.jp
Omi
Wataru
W
Yuasa
Toyoshi
T
Sakagami
Satoru
S
Takata
Shigeo
S
Kobayashi
Kenichi
K
D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000000981:diagnostic imaging* / Q000503:physiopathology; D003971:Diastole / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004452:Echocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D019337:Hematologic Neoplasms / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007564:Japan; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D013318:Stroke Volume / Q000187:drug effects; D013599:Systole / Q000187:drug effects
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin